DPP4/CD26, Mouse, 重组蛋白 (hFc) TMPY-00221
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | 价格 | 操作 |
---|---|---|
100 μg | ¥3,750.00 | 询底价 |
500 μg | ¥12,990.00 | 询底价 |
50 μg | ¥2,190.00 | 询底价 |
200 μg | ¥6,420.00 | 询底价 |
Product Introduction
Bioactivity
英文名: DPP4/CD26 Protein, Mouse, Recombinant (hFc)
描述: Dipeptidyl peptidase-4 (DPP4) or adenosine deaminase complexing protein 2 (ADCP 2) or T-cell activation antigen CD26 is a serine exopeptidase belonging to the S9B protein family that cleaves X-proline dipeptides from the N-terminus of polypeptides, such as chemokines, neuropeptides, and peptide hormones. The enzyme is a type II transmembrane glycoprotein, expressed on the surface of many cell types. It is also present in serum and other body fluids in a truncated form (sCD26/DPPIV). The soluble CD26 (sCD26) as a tumour marker for the detection of colorectal cancer (CRC) and advanced adenomas. As both a regulatory enzyme and a signalling factor, DPP4 has been evaluated and described in many studies. DPP4 inhibition results in increased blood concentration of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This causes an increase in glucose-dependent stimulation, resulting in a lowering of blood glucose levels. Recent studies have shown that DPP4 inhibitors can induce a significant reduction in glycosylated haemoglobin (HbA(1c)) levels, either as monotherapy or as a combination with other antidiabetic agents. Research has also demonstrated that DPP4 inhibitors portray a very low risk of hypoglycaemia development, and are a new pharmacological class of drugs for treating Type 2 diabetes.
存储条件: Lyophilized powder: -20~-80°C for 1 year | Solution: -80°C for 6~12 month
DPP4/CD26, Mouse, 重组蛋白 (hFc) TMPY-00221信息由TargetMol中国为您提供,如您想了解更多关于DPP4/CD26, Mouse, 重组蛋白 (hFc) TMPY-00221报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途